Bio-Technology General Corp. has begun a Phase II efficacystudy of BioTropin, its recombinant human growth hormone inpancreatic cancer patients.
Recent short-term studies have shown that cancer patientstreated with Bio-Technology General's human growth hormoneresponded to the anabolic growth hormone.
The company is also conducting clinical studies aimed atassessing the utility of human growth hormone in thetreatment of HIV-infected patients and in the prevention ofmuscle atrophy in the elderly hospitalized with hip fractures.
(c) 1997 American Health Consultants. All rights reserved.